THERION COMPLETES ENROLLMENT FOR PANVAC-VF PANCREATIC CANCER TRIAL

Therion Biologics has announced that the Phase III clinical trial for PANVAC-VF to treat metastatic pancreatic cancer patients has completed enrollment.

The randomized, controlled trial has enrolled 250 patients with pancreatic cancer who had received prior treatment with gemcitabine. The company plans to submit a biological license application (BLA) to the FDA later this year.